Berardis Silvia, Dwisthi Sattwika Prenali, Najimi Mustapha, Sokal Etienne Marc
Silvia Berardis, Prenali Dwisthi Sattwika, Mustapha Najimi, Etienne Marc Sokal, Laboratory of Pediatric Hepatology and Cell Therapy, Institut de Recherche Expérimentale et Clinique, Cliniques Universitaires St Luc, Université Catholique de Louvain, 1200 Brussels, Belgium.
World J Gastroenterol. 2015 Jan 21;21(3):742-58. doi: 10.3748/wjg.v21.i3.742.
Progressive liver fibrosis is a major health issue for which no effective treatment is available, leading to cirrhosis and orthotopic liver transplantation. However, organ shortage is a reality. Hence, there is an urgent need to find alternative therapeutic strategies. Cell-based therapy using mesenchymal stem cells (MSCs) may represent an attractive therapeutic option, based on their immunomodulatory properties, their potential to differentiate into hepatocytes, allowing the replacement of damaged hepatocytes, their potential to promote residual hepatocytes regeneration and their capacity to inhibit hepatic stellate cell activation or induce their apoptosis, particularly via paracrine mechanisms. The current review will highlight recent findings regarding the input of MSC-based therapy for the treatment of liver fibrosis, from in vitro studies to pre-clinical and clinical trials. Several studies have shown the ability of MSCs to reduce liver fibrosis and improve liver function. However, despite these promising results, some limitations need to be considered. Future prospects will also be discussed in this review.
进行性肝纤维化是一个重大的健康问题，目前尚无有效的治疗方法，最终会导致肝硬化和原位肝移植。然而，器官短缺是现实情况。因此，迫切需要找到替代治疗策略。基于间充质干细胞（MSCs）的免疫调节特性、分化为肝细胞以替代受损肝细胞的潜力、促进残余肝细胞再生的潜力以及抑制肝星状细胞激活或诱导其凋亡的能力（特别是通过旁分泌机制），利用间充质干细胞进行细胞治疗可能是一种有吸引力的治疗选择。本综述将重点介绍基于间充质干细胞治疗肝纤维化的最新研究成果，范围从体外研究到临床前和临床试验。多项研究表明间充质干细胞具有减轻肝纤维化和改善肝功能的能力。然而，尽管有这些令人鼓舞的结果，但仍需考虑一些局限性。本综述还将讨论未来的前景。
